ZA948252B - Method and composition for treatment of autoimmune hepatitis - Google Patents

Method and composition for treatment of autoimmune hepatitis

Info

Publication number
ZA948252B
ZA948252B ZA948252A ZA948252A ZA948252B ZA 948252 B ZA948252 B ZA 948252B ZA 948252 A ZA948252 A ZA 948252A ZA 948252 A ZA948252 A ZA 948252A ZA 948252 B ZA948252 B ZA 948252B
Authority
ZA
South Africa
Prior art keywords
treatment
composition
autoimmune hepatitis
hepatitis
autoimmune
Prior art date
Application number
ZA948252A
Other languages
English (en)
Inventor
Paul B Chretien
Milton G Mutchnick
Original Assignee
Alpha I Biomedicals Inc
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha I Biomedicals Inc, Univ Wayne State filed Critical Alpha I Biomedicals Inc
Publication of ZA948252B publication Critical patent/ZA948252B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
ZA948252A 1993-10-26 1994-10-20 Method and composition for treatment of autoimmune hepatitis ZA948252B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/141,013 US5468729A (en) 1993-10-26 1993-10-26 Method for treatment of autoimmune hepatitis

Publications (1)

Publication Number Publication Date
ZA948252B true ZA948252B (en) 1996-04-22

Family

ID=22493765

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA948252A ZA948252B (en) 1993-10-26 1994-10-20 Method and composition for treatment of autoimmune hepatitis

Country Status (8)

Country Link
US (1) US5468729A (enrdf_load_stackoverflow)
AU (1) AU8086894A (enrdf_load_stackoverflow)
MY (1) MY115157A (enrdf_load_stackoverflow)
PH (1) PH31319A (enrdf_load_stackoverflow)
SG (1) SG46620A1 (enrdf_load_stackoverflow)
TW (1) TW249754B (enrdf_load_stackoverflow)
WO (1) WO1995011696A1 (enrdf_load_stackoverflow)
ZA (1) ZA948252B (enrdf_load_stackoverflow)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
EP2279742A3 (en) * 2001-10-05 2011-04-20 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US20080003213A1 (en) * 2006-05-22 2008-01-03 Jan Lessem Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
ITRM20060584A1 (it) * 2006-10-27 2008-04-28 Francesco Bistoni Uso della timosina alfa 1 la preparazione di un medicamento per la prevenzione e la cura delle malattie autoimmuni
EP2427213B1 (en) * 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CN117065050A (zh) 2011-04-29 2023-11-17 西莱克塔生物科技公司 用于降低细胞毒性t淋巴细胞应答的致耐受性合成纳米载体
JP2016520051A (ja) 2013-05-03 2016-07-11 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． Ｉ型およびｉｖ型過敏症を低減させる寛容原性の合成ナノ担体の局所的な併用投与
AU2015311708A1 (en) 2014-09-07 2017-02-02 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
EP3592389B1 (en) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
TW224053B (enrdf_load_stackoverflow) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
MX9408106A (es) 1997-09-30
US5468729A (en) 1995-11-21
PH31319A (en) 1998-07-06
TW249754B (enrdf_load_stackoverflow) 1995-06-21
SG46620A1 (en) 1998-02-20
MY115157A (en) 2003-04-30
AU8086894A (en) 1995-05-22
WO1995011696A1 (en) 1995-05-04

Similar Documents

Publication Publication Date Title
AP9300598A0 (en) Compositions and method for waste treatment
EP0717592A4 (en) METHOD AND COMPOSITION FOR TREATING THE APATHIE DEMOTIVATION SYNDROME
HU9502565D0 (en) Method of treating solid waste
ZA948252B (en) Method and composition for treatment of autoimmune hepatitis
GB9014307D0 (en) Method of treatment and compositions therefor
ZA931778B (en) Method and composition for the treatment of osteoporosis
PL300549A1 (en) Structural component and method of making same
ZA935055B (en) Composition and method of treating hepatitis b
GB9414227D0 (en) Antiperspirant composition and method of use thereof
PL301204A1 (en) Method of obtaining avermectines and invermectines
PL313740A1 (en) Method of
PL311268A1 (en) Cholestyramine containing composition and method of obtaining same
EP0472595A4 (en) Method of treatment of hepatitis
AU4104093A (en) Method and compositions for treatment of pyonecrotic processes
GB9224295D0 (en) Method and composition
GB9420539D0 (en) Process and composition
EP0472663A4 (en) Method of treatment of hepatitis
GB9202196D0 (en) Method of treatment
PL303822A1 (en) Therapeutic compositions containing ipsapyrone and method of obtaining them
PL306335A1 (en) Tank and method of making same
CS61691A2 (en) Composition for dung-water treatment and method of dung-water treatment
AU5467198A (en) Composition and method of treating hepatitis B
SG66305A1 (en) Composition and method for treatment of phoshated surfaces
GB9201391D0 (en) Method of treatment
GB9308051D0 (en) Method and composition